Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 7/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.38 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162033 | 0.93 | TGFBR1 (0.42) | TGFBR1CYP3A4CYP2C8JAK1EGFR | |
| SCHEMBL4163539 | 0.92 | TGFBR1 (0.44) | TGFBR1CYP3A4CYP2C8JAK1EGFR | |
| SCHEMBL4157078 | 0.86 | CYP3A4 (0.41) | TGFBR1CYP3A4CYP2C8JAK1PDCD1 | |
| SCHEMBL4155020 | 0.80 | TGFBR1 (0.46) | TGFBR1CYP3A4CYP2C8JAK1TGFBR2 | |
| SCHEMBL4155882 | 0.80 | TGFBR1 (0.41) | TGFBR1CYP3A4CYP2C8JAK1CD274 | |
| SCHEMBL4153816 | 0.79 | TGFBR1 (0.40) | TGFBR1CYP3A4CYP2C8JAK1EGFR | |
| SCHEMBL27808359 | 0.78 | TGFBR1 (0.39) | TGFBR1CYP3A4CYP2C8JAK1NEK1 | |
| SCHEMBL3664985 | 0.78 | TGFBR1 (0.47) | TGFBR1CYP3A4CYP2C8JAK1EGFR | |
| SCHEMBL3803691 | 0.77 | TGFBR1 (0.43) | TGFBR1CYP3A4CYP2C8JAK1NEK1 | |
| SCHEMBL4155516 | 0.76 | PDCD1 (0.38) | TGFBR1CYP3A4CYP2C8EGFRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | TGFBR1 128/4885CYP3A4 111/4885CYP2C8 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.